Udayavni Special

Covid-19: Jubilant Life Sciences launches generic version of remdesivir

PTI, Aug 4, 2020, 10:42 AM IST

Drug firm Jubilant Life Sciences on Monday, August 3 said it has launched the generic version of antiviral drug remdesivir in India for the treatment of Covid-19 patients.

The injectable drug, under the brand name ‘JUBI-R’, is priced at Rs 4,700 per vial of 100 mg.

The company will make the drug available to over 1,000 hospitals providing Covid-19 treatment, Jubilant Life Sciences said in a statement.

In order to increase the accessibility of the drug to patients below the poverty line and to front-line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organization of the Jubilant Group, is launching programs in India aimed at its distribution, it added.

“We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and in other countries,” Jubilant Pharma Chairman and MD Shyam S Bhartia and Co-Chairman Hari S Bhartia said in the statement.

The company’s ability to launch this product in such short timelines highlights “our R&D and manufacturing capabilities and our continued commitment to providing leading healthcare solutions”, they added.

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences Inc that granted it the right to register, manufacture and sell the US-based firm’s investigational drug remdesivir in 127 countries, including India, the statement said.

“On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe Covid-19,” it added.

“The drug will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner,” the statement said.

“Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) for the treatment of suspected or laboratory-confirmed Covid-19 in adults and children hospitalized with severe disease,” it added.

Shares of Jubilant Life Sciences closed at Rs 862.30 per scrip on BSE, up 8.42 percent from its previous close.

Top News

K’taka COVID-19 update: 6997 new cases, 5460 discharges, 38 deaths on Sep 22

MoS Railways Suresh Angadi passes away

Delhi Deputy CM Manish Sisodia hospitalised due to Covid-19

CMS gets contract from Karnataka Bank, Paytm for home delivery of cash

PM reviews COVID-19 situation with CMs, representatives of 7 states with high case load

NCB summons Deepika, Shraddha Kapoor, Sara Ali Khan in drugs case

Eiffel Tower evacuated over bomb threat

Related Articles More

K’taka COVID-19 update: 6997 new cases, 5460 discharges, 38 deaths on Sep 22

Covid-19: MLA Narayan Rao’s condition critical

Amid COVID-19 impact, Indian economy forecast to contract 5.4% in 2020: UN

Trump hits out at China for not stopping COVID-19; calls it Chinese virus yet again

Deputy CM Govind Karjol tests positive for COVID-19


‘Road Politics in Times of Pandemic’: St Aloysius Institution reacts to road renaming

Mangaluru Light House Hill Road renamed as Mulki Sunder Ram Shetty Road

Soraba : District Excise Department seized Millions worth of Marijuana | Udayavani

Hospet : Tungabhadra Dam Gates Are Opened | TB Dam | Udayavani

Surathkal: Police arrest four in house burglary case

Latest Additions

K’taka COVID-19 update: 6997 new cases, 5460 discharges, 38 deaths on Sep 22

MoS Railways Suresh Angadi passes away

Hanur: Police find sandalwood along with marijuana during raid

Mercedes Benz launches AMG GLE 53 4MATIC+ Coupe at Rs 1.2 cr

Kukke Subramanya temple to restart ritual offerings at evening

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.